B
BHC
Bausch Health Companies Inc
$5.89
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Bausch Health Companies Inc in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$2.96
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: $1.29
Oct 28
Posts
No posts about BHC yet.
About Bausch Health Companies Inc
Bausch Health Companies is a Canadian pharmaceutical company that sells medicines and health products around the world. It makes money through several units: eye care and contact lenses, mostly through its majority-owned Bausch + Lomb business, a gastrointestinal drug line built around its bestseller Xifaxan, plus dermatology and neurology treatments. The company was formerly known as Valeant Pharmaceuticals and still carries a heavy debt load from that era's acquisition spree.